

## **Global Cardiac Biomarker Testing Market Report and Forecast 2024-2032**

Market Report | 2023-09-18 | 140 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

### **Report description:**

Global Cardiac Biomarker Testing Market Report and Forecast 2024-2032

Global Cardiac Biomarker Testing Market Outlook

The global cardiac biomarker testing market size was valued at USD 4.7 billion in 2023, driven by the increasing prevalence of cardiovascular diseases across the globe. The market size is anticipated to grow at a CAGR of 8.8% during the forecast period of 2024-2032 to achieve a value of USD 10 billion by 2032.

Cardiac Biomarker Testing: Introduction

Cardiac biomarker testing, also known as cardiac marker testing, refers to the measurement of specific substances or molecules in the blood that are released into the bloodstream when there is damage to the heart or its muscles. These biomarkers play a crucial role in the diagnosis, risk assessment, and management of various cardiac conditions, including heart attacks (myocardial infarctions), heart failure, and other cardiovascular diseases. Cardiac biomarker testing provides valuable information to healthcare professionals for timely intervention and patient care. Some common cardiac biomarkers include:

-  Troponin: Troponin is one of the most sensitive and specific cardiac biomarkers. It is released into the bloodstream when there is damage to the heart muscle, such as during a heart attack. Troponin levels rise within hours of cardiac injury and remain elevated for several days.

-  Creatine Kinase-MB (CK-MB): CK-MB is an enzyme found predominantly in heart muscle cells. Elevated CK-MB levels indicate heart muscle damage and are often used in conjunction with troponin measurements to confirm a heart attack.

-  Myoglobin: Myoglobin is a protein found in heart and skeletal muscles. It is a less specific cardiac biomarker compared to troponin and CK-MB, but elevated myoglobin levels can suggest heart muscle damage.

Key Trends in the Global Cardiac Biomarker Testing Market

Here are some key trends in the market:

-  The field of cardiac biomarker testing continues to evolve with advancements in technology, changes in healthcare practices, and an emphasis on early diagnosis and precision medicine. As of my last knowledge update in September 2021, here are some notable trends in the cardiac biomarker testing market:

-  High-Sensitivity Cardiac Troponin Assays: High-sensitivity cardiac troponin assays are becoming more widespread. These assays

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

can detect even minor elevations in troponin levels, enabling earlier diagnosis of acute myocardial infarction (heart attack) and improved risk assessment.

-□Multi-Biomarker Panels: Rather than relying solely on a single biomarker, healthcare providers are increasingly using multi-biomarker panels. Combining different cardiac biomarkers provides a more comprehensive picture of a patient's cardiac health and can enhance diagnostic accuracy.

-□Point-of-Care Testing (POCT): Point-of-care cardiac biomarker testing is gaining popularity for rapid assessment of cardiac conditions in emergency departments and ambulances. POCT devices allow for faster decision-making and triage of patients with chest pain or suspected heart attacks.

-□Personalized Medicine: The concept of personalized medicine is extending to cardiac biomarker testing. Genetic factors and individual patient profiles are increasingly considered when interpreting biomarker results and tailoring treatment plans.

-□Use of Artificial Intelligence (AI): AI and machine learning algorithms are being employed to analyze complex biomarker data, predict cardiac events, and assist in risk stratification. These technologies can enhance the precision of diagnosis and treatment decisions.

-□Expanded Clinical Applications: Beyond diagnosing heart attacks and heart failure, cardiac biomarker testing is finding applications in predicting and monitoring other cardiovascular conditions, such as atrial fibrillation, cardiac arrhythmias, and valvular heart disease.

#### Global Cardiac Biomarker Testing Market Segmentations

The market can be categorized into testing type, technology, biomarker type, applications, end user, and region.

##### Market Breakup by Testing Type

- Point of Care Testing (POCT)
- Laboratory Testing

##### Market Breakup by Technology

- Immunoassay
- Clinical Chemistry
- Molecular Diagnostics
- Others

##### Market Breakup by Biomarker Type

- Creatine Kinase (CK-MB)
- Troponins
- Myoglobin
- Natriuretic Peptides (BNP and NT-proBNP)
- Ischemia Modified Albumins
- Other Biomarkers

##### Market Breakup by Applications

- Myocardial Infraction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Other Applications

##### Market Breakup by End User

- Hospitals and Clinics
- Diagnostic Laboratories
- Ambulatory Surgical Centres

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Research Institutes
- Others

#### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

#### Global Cardiac Biomarker Testing Market Overview

Here are some key drivers for the cardiac biomarker testing market:

- Rising Cardiovascular Disease Burden: Cardiovascular diseases, including coronary artery disease, heart failure, and arrhythmias, continue to be a leading cause of morbidity and mortality globally. The increasing prevalence of these conditions drives the demand for cardiac biomarker testing for early diagnosis and management.
- Aging Population: The aging demographic trend results in a higher incidence of heart-related conditions, making cardiac biomarker testing essential for the elderly population.
- Preventive Medicine: There is a growing emphasis on preventive healthcare, and cardiac biomarker testing plays a role in identifying individuals at risk of developing cardiovascular diseases, allowing for early intervention and lifestyle modifications.
- Technological Advancements: Ongoing advancements in biomarker assay technologies, including high-sensitivity assays, enable more accurate and earlier detection of cardiac biomarkers, improving diagnostic capabilities.
- Point-of-Care Testing (POCT): The availability of point-of-care cardiac biomarker testing devices allows for rapid assessment and triage of patients in emergency departments and ambulances, leading to quicker treatment decisions.
- Personalized Medicine: Cardiac biomarker testing is increasingly used to tailor treatment plans to individual patient profiles, including genetic factors and biomarker levels, optimizing therapy and outcomes.

#### Cardiac Biomarker Testing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Beckman Coulter, Inc. (Danaher Corporation)
- bioMérieux SA
- Ortho Clinical Diagnostics
- Becton, Dickinson and Company (BD)
- Thermo Fisher Scientific Inc.
- Randox Laboratories Ltd.
- Bio-Rad Laboratories, Inc.
- Singulex Inc.
- Abbott
- LSI Medience Corporation
- Trivitron Healthcare
- Qingdao Rich Biotechnology Co., Ltd.
- Werfen
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Guangzhou Wondfo Biotech Co., Ltd.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-□Abnova Corporation  
-□Merck KGaA

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

## **Table of Contents:**

- 1Preface
- 1.1Objectives of the Study
- 1.2Key Assumptions
- 1.3Report Coverage - Key Segmentation and Scope
- 1.4Research Methodology
- 2Executive Summary
- 3Global Cardiac Biomarker Testing Market Overview
  - 3.1Global Cardiac Biomarker Testing Market Historical Value (2017-2023)
  - 3.2Global Cardiac Biomarker Testing Market Forecast Value (2024-2032)
- 4Global Cardiac Biomarker Testing Market Landscape
  - 4.1Global Cardiac Biomarker Testing Developers Landscape
    - 4.1.1Analysis by Year of Establishment
    - 4.1.2Analysis by Company Size
    - 4.1.3Analysis by Region
  - 4.2Global Cardiac Biomarker Testing Product Landscape
    - 4.2.1Analysis by Type
    - 4.2.2Analysis by Technology
    - 4.2.3Analysis by Applications
- 5Global Cardiac Biomarker Testing Market Dynamics
  - 5.1Market Drivers and Constraints
  - 5.2SWOT Analysis
  - 5.3Porter's Five Forces Model
  - 5.4Key Demand Indicators
  - 5.5Key Price Indicators
  - 5.6Industry Events, Initiatives, and Trends
  - 5.7Value Chain Analysis
- 6Global Cardiac Biomarker Testing Market Segmentation
  - 6.1Global Cardiac Biomarker Testing Market by Testing Type
    - 6.1.1Market Overview
    - 6.1.2Point of Care Testing (POCT)
    - 6.1.3Laboratory Testing
  - 6.2Global Cardiac Biomarker Testing Market by Technology
    - 6.2.1Market Overview
    - 6.2.2Immunoassay
    - 6.2.3Clinical Chemistry
    - 6.2.4Molecular Diagnostics
    - 6.2.5Others
  - 6.3Global Cardiac Biomarker Testing Market by Biomarker Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.1Market Overview
- 6.3.2Creatine Kinase (CK-MB)
- 6.3.3Troponins
- 6.3.4Myoglobin
- 6.3.5Natriuretic Peptides (BNP and NT-proBNP)
- 6.3.6Ischemia Modified Albumins
- 6.3.7Other Biomarkers
- 6.4Global Cardiac Biomarker Testing Market by Applications
- 6.4.1Market Overview
- 6.4.2Myocardial Infraction
- 6.4.3Congestive Heart Failure
- 6.4.4Acute Coronary Syndrome
- 6.4.5Atherosclerosis
- 6.4.6Other Applications
- 6.5Global Cardiac Biomarker Testing Market by End User
- 6.5.1Market Overview
- 6.5.2Hospitals and Clinics
- 6.5.3Diagnostic Laboratories
- 6.5.4Ambulatory Surgical Centers
- 6.5.5Research Institutes
- 6.5.6Others
- 6.6Global Cardiac Biomarker Testing Market by Region
- 6.6.1Market Overview
- 6.6.2North America
- 6.6.3Europe
- 6.6.4Asia Pacific
- 6.6.5Latin America
- 6.6.6Middle East and Africa
- 7North America Cardiac Biomarker Testing Market
- 7.1Market Share by Country
- 7.2United States of America
- 7.3Canada
- 8Europe Cardiac Biomarker Testing Market
- 8.1Market Share by Country
- 8.2United Kingdom
- 8.3Germany
- 8.4France
- 8.5Italy
- 8.6Others
- 9Asia Pacific Cardiac Biomarker Testing Market
- 9.1Market Share by Country
- 9.2China
- 9.3Japan
- 9.4India
- 9.5ASEAN
- 9.6Australia
- 9.7Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10Latin America Cardiac Biomarker Testing Market
  - 10.1Market Share by Country
  - 10.2Brazil
  - 10.3Argentina
  - 10.4Mexico
  - 10.5Others
- 11Middle East and Africa Cardiac Biomarker Testing Market
  - 11.1Market Share by Country
  - 11.2Saudi Arabia
  - 11.3United Arab Emirates
  - 11.4Nigeria
  - 11.5South Africa
  - 11.6Others
- 12Patent Analysis
  - 12.1Analysis by Type of Patent
  - 12.2Analysis by Publication year
  - 12.3Analysis by Issuing Authority
  - 12.4Analysis by Patent Age
  - 12.5Analysis by CPC Analysis
  - 12.6Analysis by Patent Valuation
  - 12.7Analysis by Key Players
- 13Grants Analysis
  - 13.1Analysis by year
  - 13.2Analysis by Amount Awarded
  - 13.3Analysis by Issuing Authority
  - 13.4Analysis by Grant Application
  - 13.5Analysis by Funding Institute
  - 13.6Analysis by NIH Departments
  - 13.7Analysis by Recipient Organization
- 14Funding Analysis
  - 14.1Analysis by Funding Instances
  - 14.2Analysis by Type of Funding
  - 14.3Analysis by Funding Amount
  - 14.4Analysis by Leading Players
  - 14.5Analysis by Leading Investors
  - 14.6Analysis by Geography
- 15Partnership and Collaborations Analysis
  - 15.1Analysis by Partnership Instances
  - 15.2Analysis by Type of Partnership
  - 15.3Analysis by Leading Players
  - 15.4Analysis by Geography
- 16Regulatory Framework
  - 16.1Regulatory Overview
    - 16.1.1US FDA
    - 16.1.2EU EMA
    - 16.1.3INDIA CDSCO
    - 16.1.4JAPAN PMDA

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.1.5Others
- 17Supplier Landscape
  - 17.1Abbott Laboratories
    - 17.1.1Financial Analysis
    - 17.1.2Product Portfolio
    - 17.1.3Demographic Reach and Achievements
    - 17.1.4Mergers and Acquisition
    - 17.1.5Certifications
  - 17.2F. Hoffmann-La Roche Ltd.
    - 17.2.1Financial Analysis
    - 17.2.2Product Portfolio
    - 17.2.3Demographic Reach and Achievements
    - 17.2.4Mergers and Acquisition
    - 17.2.5Certifications
  - 17.3Siemens Healthineers AG
    - 17.3.1Financial Analysis
    - 17.3.2Product Portfolio
    - 17.3.3Demographic Reach and Achievements
    - 17.3.4Mergers and Acquisition
    - 17.3.5Certifications
  - 17.4Beckman Coulter, Inc. (Danaher Corporation)
    - 17.4.1Financial Analysis
    - 17.4.2Product Portfolio
    - 17.4.3Demographic Reach and Achievements
    - 17.4.4Mergers and Acquisition
    - 17.4.5Certifications
  - 17.5bioMerieux SA
    - 17.5.1Financial Analysis
    - 17.5.2Product Portfolio
    - 17.5.3Demographic Reach and Achievements
    - 17.5.4Mergers and Acquisition
    - 17.5.5Certifications
  - 17.6Ortho Clinical Diagnostics
    - 17.6.1Financial Analysis
    - 17.6.2Product Portfolio
    - 17.6.3Demographic Reach and Achievements
    - 17.6.4Mergers and Acquisition
    - 17.6.5Certifications
  - 17.7Becton, Dickinson and Company (BD)
    - 17.7.1Financial Analysis
    - 17.7.2Product Portfolio
    - 17.7.3Demographic Reach and Achievements
    - 17.7.4Mergers and Acquisition
    - 17.7.5Certifications
  - 17.8Thermo Fisher Scientific Inc.
    - 17.8.1Financial Analysis
    - 17.8.2Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 Randox Laboratories Ltd.
  - 17.9.1 Financial Analysis
  - 17.9.2 Product Portfolio
  - 17.9.3 Demographic Reach and Achievements
  - 17.9.4 Mergers and Acquisition
  - 17.9.5 Certifications
- 17.10 Bio-Rad Laboratories, Inc.
  - 17.10.1 Financial Analysis
  - 17.10.2 Product Portfolio
  - 17.10.3 Demographic Reach and Achievements
  - 17.10.4 Mergers and Acquisition
  - 17.10.5 Certifications
- 17.11 Singulex Inc.
  - 17.11.1 Financial Analysis
  - 17.11.2 Product Portfolio
  - 17.11.3 Demographic Reach and Achievements
  - 17.11.4 Mergers and Acquisition
  - 17.11.5 Certifications
- 17.12 Abbott
  - 17.12.1 Financial Analysis
  - 17.12.2 Product Portfolio
  - 17.12.3 Demographic Reach and Achievements
  - 17.12.4 Mergers and Acquisition
  - 17.12.5 Certifications
- 17.13 LSI Medience Corporation
  - 17.13.1 Financial Analysis
  - 17.13.2 Product Portfolio
  - 17.13.3 Demographic Reach and Achievements
  - 17.13.4 Mergers and Acquisition
  - 17.13.5 Certifications
- 17.14 Trivitron Healthcare
  - 17.14.1 Financial Analysis
  - 17.14.2 Product Portfolio
  - 17.14.3 Demographic Reach and Achievements
  - 17.14.4 Mergers and Acquisition
  - 17.14.5 Certifications
- 17.15 Qingdao Rich Biotechnology Co., Ltd.
  - 17.15.1 Financial Analysis
  - 17.15.2 Product Portfolio
  - 17.15.3 Demographic Reach and Achievements
  - 17.15.4 Mergers and Acquisition
  - 17.15.5 Certifications
- 17.16 Werfen
  - 17.16.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.16.2Product Portfolio
- 17.16.3Demographic Reach and Achievements
- 17.16.4Mergers and Acquisition
- 17.16.5Certifications
- 17.17Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 17.17.1Financial Analysis
- 17.17.2Product Portfolio
- 17.17.3Demographic Reach and Achievements
- 17.17.4Mergers and Acquisition
- 17.17.5Certifications
- 17.18Guangzhou Wondfo Biotech Co., Ltd.
- 17.18.1Financial Analysis
- 17.18.2Product Portfolio
- 17.18.3Demographic Reach and Achievements
- 17.18.4Mergers and Acquisition
- 17.18.5Certifications
- 17.19Abnova Corporation
- 17.19.1Financial Analysis
- 17.19.2Product Portfolio
- 17.19.3Demographic Reach and Achievements
- 17.19.4Mergers and Acquisition
- 17.19.5Certifications
- 17.20Merck KGaA
- 17.20.1Financial Analysis
- 17.20.2Product Portfolio
- 17.20.3Demographic Reach and Achievements
- 17.20.4Mergers and Acquisition
- 17.20.5Certifications
- 18Global Cardiac Biomarker Testing Market - Distribution Model (Additional Insight)
- 18.1Overview
- 18.2Potential Distributors
- 18.3Key Parameters for Distribution Partner Assessment
- 19Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20Company Competitiveness Analysis (Additional Insight)
- 20.1Very Small Companies
- 20.2Small Companies
- 20.3Mid-Sized Companies
- 20.4Large Companies
- 20.5Very Large Companies
- 21Payment Methods (Additional Insight)
- 21.1Government Funded
- 21.2Private Insurance
- 21.3Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Global Cardiac Biomarker Testing Market Report and Forecast 2024-2032**

Market Report | 2023-09-18 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com